FDA Program for Reducing Unsafe Opioid Prescribing and Adverse Events Fails to Produce Clear Results
It is unclear whether the government’s strategy for reducing unsafe opioid prescribing and adverse e...
An independent advisory panel to the Food and Drug Administration (FDA) on Tuesday endorsed the eske...
Last month, the FDA announced that beginning on October 12, all prescribers of clozapine—a medicatio...
